Disease-modifying antirheumatic drugs: Enhancing efficacy by combination

Lancet

Volumn 363, Issue 9410, 2004, Pages 670-671

  Schnabel, Armin ^a  

^a SANA KLINIKUM OFFENBACH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; CYCLOSPORIN A; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE;

CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SCREENING; DRUG TOLERABILITY; HUMAN; NOTE; PHARMACEUTICAL CARE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

EID: 1542331575     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)15660-2     Document Type: Note

References (10)

1. Emery P. Evidence supporting the benefit of early intervention in rheumatoid arthritis. J Rheumatol. 29:(suppl 66):2002;3-8.
2. Pincus T., O'Dell J.R., Kremer J.M. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. Ann Intern Med. 131:1999;768-774.
3. Maini R., St Clair E.W., Breedveld F., et al. Infliximab (chimeric anti-tumor necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet. 354:1999;1932-1939.
4. Weinblatt M.E., Kremer J.M., Bankhurst A.D., et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 340:1999;253-259.
5. Weinblatt M.E., Keystone E.C., Furst D.E., et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. Arthritis Rheum. 48:2003;35-45.
6. Genovese M.C., Bathon J.M., Martin R.W., et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 46:2002;1443-1450.
7. Van der Heide A., Jacobs J.W.G., Bijlsma W.J., et al. The effectiveness of early treatment with "second-line"antirheumatic drugs. A randomized, controlled trial. Ann Intern Med. 124:1996;699-707.
8. Möttönen T., Hannonen P., Korpela M., et al. Delay to institution and induction of remission using single-drug or combination-disease- modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum. 46:2002;894-898.
9. Van Jaarsveld CH, Jacobs JW, van der Veen MJ, on behalf of the Rheumatic Research Foundation Utrecht, The Netherlands. Aggressive treatment in early rheumatoid arthritis: a randomized controlled trial. Ann Rheum Dis 2000; 59: 468-77.
10. Landewé R.B.M., Boers M., Verhoeven A.C., et al. COBRA combination therapy in patients with early rheumatoid arthritis: Long-term benefits of a brief intervention. Arthritis Rheum. 46:2002;347-356.